The Hepatitis C Virus Modulates Insulin Signaling Pathway In Vitro Promoting Insulin Resistance

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  del Campo, José A ^a   García Valdecasas, Marta ^a   Rojas, Lourdes ^a   Rojas, Ángela ^a   Romero Gómez, Manuel ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN RECEPTOR SUBSTRATE 1; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE 1B; STAT1 PROTEIN;

AKT GENE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; GENE; GENE EXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; INSULIN METABOLISM; INSULIN RESISTANCE; IRS1 GENE; MAP3K GENE; NONHUMAN; PI3K GENE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PTEN GENE; PTP1B GENE; SIGNAL TRANSDUCTION; STAT1 GENE; UPREGULATION; VIRUS PARTICLE; VIRUS REPLICATION; BIOLOGICAL MODEL; CELL LINE; COMORBIDITY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; METABOLISM; STATISTICAL MODEL;

HEPATITIS C VIRUS;

CELL LINE; COMORBIDITY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, VIRAL; HEPACIVIRUS; HEPATITIS C; HUMANS; INSULIN; INSULIN RESISTANCE; METFORMIN; MODELS, BIOLOGICAL; MODELS, STATISTICAL; SIGNAL TRANSDUCTION;

EID: 84868088948     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047904     Document Type: Article

References (30)

1. Bressler BL, Guindi M, Tomlinson G, Heathcote J, (2003) High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology. 38: 639-44.
2. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, et al. (2003) Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 38: 75-85.
3. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, et al. (2005) Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128: 636-641.
4. Romero-Gómez M, Diago M, Andrade RJ, Calleja JL, Salmerón J, et al. (2009) Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 50: 1702-8.
5. Chojkier M, Elkhayat H, Sabry D, Donohue M, Buck M, (2012) Pioglitazone decreases hepatitis C viral load in overweight, treatment naïve, genotype 4 infected-patients: a pilot study. PLoS One 7: e31516.
6. Harrison SA, Hamzeh FM, Han J, Pandya PK, Sheikh MY, et al. (2012) Chronic hepatitis c genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alfa-2a plus ribavirin. Hepatology doi:10.1002/hep.25661.
7. Pazienza V, Clément S, Pugnale P, Conzelman S, Foti M, et al. (2007) The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology 45: 1164-1171.
8. Banerjee S, Saito K, Ait-Goughoulte M, Meyer K, Ray RB, et al. (2008) Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance. J Virol 82: 2606-2612.
9. White MF, (2003) Insulin signaling in health and disease. Science 302: 1710-1711.
10. Ogawa W, Matozaki T, Kasuga M, (1998) Role of binding proteins to IRS-1 in insulin signalling. Mol Cell Biochem 182: 13-22.
11. Machado-Neto JA, Favaro P, Lazarini M, Costa FF, Olalla Saad ST, et al. (2011) Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells. Biochim Biophys Acta 1813: 1404-11.
12. Zoncu R, Efeyan A, Sabatini DM, (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35.
13. Haque A, Andersen JN, Salmeen A, Barford D, Tonks NK, (2011) Conformation-sensing antibodies stabilize the oxidized form of PTP1B and inhibit its phosphatase activity. Cell 147: 185-98.
14. Zhou G, Myers R, Li Y, Chen Y, Shen X, et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-74.
15. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M, (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66: 10269-73.
16. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N, (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67: 10804-12.
17. García-Ruiz I, Solís-Muñoz P, Gómez-Izquierdo E, Muñoz-Yagüe MT, Valverde AM, et al. (2012) Protein-tyrosine Phosphatases Are Involved in Interferon Resistance Associated with Insulin Resistance in HepG2 Cells and Obese Mice. J Biol Chem. 287(23): 19564-73.
18. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, et al. (2005) Complete replication of hepatitis C virus in cell culture. Science 309: 623-6.
19. Altomonte J, Richter A, Harbaran S, Suriawinata J, Nakae J, et al. (2003) Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice. Am. J. Physiol. Endocrinol. Metab. 285: E718-28.
20. Matsumoto M, Han S, Kitamura T, Accili D, (2006) Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J. Clin. Invest. 116: 2464-2472.
21. Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, et al. (2003) Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 423: 550-555.
22. Samuel VT, Choi CS, Phillips TG, Romanelli AJ, Geisler JG, et al. (2006) Targeting foxo1 in mice using antisense oligonucleotide improves hepatic and peripheral insulin action. Diabetes 55: 2042-2050.
23. Cheng A, Uetani N, Simoncic PD, Chaubey VP, Lee-Loy A, et al. (2002) Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev Cell 2: 497-503.
24. Ma YM, Tao RY, Liu Q, Li J, Tian JY, et al. (2011) PTP1B inhibitor improves both insulin resistance and lipid abnormalities in vivo and in vitro. Mol Cell Biochem. 357: 65-72.
25. González-Rodríguez A, Mas Gutierrez JA, Sanz-González S, Ros M, Burks DJ, et al. (2010) Inhibition of PTP1B restores IRS1-mediated hepatic insulin signaling in IRS2-deficient mice. Diabetes 59: 588-99.
26. Nakashima K, Takeuchi K, Chihara K, Hotta H, Sada K, (2011) Inhibition of hepatitis C virus replication through adenosine monophosphate-activated protein kinase-dependent and-independent pathways. Microbiol Immunol. 55: 774-82.
27. Shi WY, Xiao D, Wang L, Dong LH, Yan ZX, et al. (2012) Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis 3: e275 doi: 10.1038/cddis.2012.13.
28. Peng L, Liang D, Tong W, Li J, Yuan Z, (2010) Hepatitis C virus NS5A activates the mammalian target of rapamycin (mTOR) pathway, contributing to cell survival by disrupting the interaction between FK506-binding protein 38 (FKBP38) and mTOR. J Biol Chem. 285: 20870-81.
29. Jager J, Grémeaux T, Gonzalez T, Bonnafous S, Debard C, et al. (2010) Tpl2 kinase is upregulated in adipose tissue in obesity and may mediate interleukin-1beta and tumor necrosis factor-{alpha} effects on extracellular signal-regulated kinase activation and lipolysis. Diabetes 59: 61-70.
30. Clément S, Peyrou M, Sanchez-Pareja A, Bourgoin L, Ramadori P, et al. (2011) Down-regulation of phosphatase and tensin homolog by hepatitis C virus core 3a in hepatocytes triggers the formation of large lipid droplets. Hepatology 54: 38-49.